

- A. Patients with clinical features of iTTP (microangiopathic hemolytic anemia, severe thrombocytopenia [platelets $< 30 \times 10^9/L$] and mild renal involvement [serum creatinine $> 2.27 \text{ mg/dL}$; $200 \mu\text{mol/L}$] that are predictive of severe ADAMTS13 deficiency¹;
- B. Unavailability/limited access to plasma exchange (context of SARS-CoV-2 pandemic); without possibility of transfer to a site with capabilities
- A. 10-15 cc/kg daily until normal platelet count ($>150 \times 10^9/L$ for 2 days and normalized LDH as tolerated, based on volume status and ability to manage the volume of plasma infused
- B. :
- Prednisone or Prednisolone 1.0-1.